Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension (ALERT-PA)
Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension
About this trial
This is an interventional screening trial for Primary Aldosteronism focused on measuring Computer Decision Support, Primary Aldosteronism
Eligibility Criteria
Inclusion Criteria: Adults 18+ Seen by clinician at one of the intervention practices at least once in the prior 2 years History of Hypertension (ICD Code) PLUS ≥1 of the below: Outpatient BP >150/100 on 2 or more occasions Three or more current antihypertensive medication prescriptions Potassium level <3.5mEq/L or potassium supplement prescription in the last 5 years History of Atrial Fibrillation or Atrial Flutter (ICD Code) Exclusion Criteria: History of Primary Aldosteronism (ICD Code) Prescription for a Mineralocorticoid Receptor Antagonist (MRA) within the last 3 months
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
BPA Alert Intervention
No Alert Intervention
An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.
No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.